Last reviewed · How we verify
NCT07104175
Predictive Value of NRS2002 and GLIM for Complications After GI Malignancy Surgery
trial in Gastrointestinal Malignancies in 471 participants. Completed in 1 January 2025.
1 January 2025
Quick facts
| Lead sponsor | Third central hospital of Tianjin affiliated Nankai university |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 471 |
| Start date | 1 December 2019 |
| Primary completion | 1 January 2025 |
| Estimated completion | 1 January 2025 |
| Sites | 1 location across China |
Conditions studied
- Gastrointestinal Malignancies — all drugs for Gastrointestinal Malignancies →
Sponsor
Third central hospital of Tianjin affiliated Nankai university
Who can join
18 and older, any sex, with Gastrointestinal Malignancies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This prospective cohort study investigates and compares the predictive power of two nutritional assessment tools, the Nutritional Risk Screening 2002 (NRS2002) and the Global Leadership Initiative on Malnutrition (GLIM) criteria. The study aims to determine how well these tools can predict postoperative complications in patients with gastrointestinal malignancies who are undergoing surgical resection.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07104175
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastrointestinal Malignancies
Currently open trials in the same condition.
- NCT06644274 — The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Gastrointestinal Malignancies · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07104175 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Third central hospital of Tianjin affiliated Nankai university
- Last refreshed: 5 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07104175.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing